Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid Tumors
Sponsor: Treeline Biosciences, Inc.
Summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Official title: An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-07-25
Completion Date
2030-08-29
Last Updated
2026-07-20
Healthy Volunteers
No
Conditions
Interventions
TLN-499
Specified dose on specified days
Venetoclax
Specified dose on specified days
Locations (3)
COBL Clinical Trials - Christ O'Brien Lifehouse
Camperdown, New South Wales, Australia
Cabrini Hospital Malvern
Malvern, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia